Clinical trial

A Study of IBI362 in Participants With Type 2 Diabetes

NCT05606913

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2023-01-06

PhasePHASE3

Study timeline

Study start (actual)2023-01-06Date precision: day

Registry last updated2024-08-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetesunresolved

Interventions

dulaglutideDRUG · verified · RxNorm: dulaglutide

IBI362DRUG

Sponsors & collaborators

Innovent Biologics (Suzhou) Co. Ltd.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05606913 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.